BerandaANTH • OTCMKTS
add
Anthera Pharmaceuticals Inc
Tutup sebelumnya
$0,00
Rentang hari
$0,00 - $0,00
Kapitalisasi pasar
26,18 USD
Volume Rata-Rata
3,68 rb
Rasio P/E
-
Hasil dividen
-
Bursa utama
OTCMKTS
Berita pasar
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | 2017info | Perubahan Y/Y |
|---|---|---|
Pendapatan | — | — |
Biaya operasional | 7,94 jt | -28,30% |
Laba bersih | -26,87 jt | 51,60% |
Margin laba bersih | — | — |
Penghasilan per saham | -3,80 | 70,53% |
EBITDA | -36,15 jt | 36,48% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
| (USD) | 2017info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 2,20 jt | -89,46% |
Total aset | 3,67 jt | -84,35% |
Total liabilitas | 9,17 jt | -13,70% |
Total ekuitas | -5,50 jt | — |
Saham yang beredar | 23,40 jt | — |
Harga terhadap nilai buku | -0,00 | — |
Tingkat pengembalian aset | -167,77% | — |
Tingkat pengembalian modal | -619,42% | — |
Arus Kas
Perubahan kas bersih
| (USD) | 2017info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -26,87 jt | 51,60% |
Kas dari operasi | -36,90 jt | 24,57% |
Kas dari investasi | — | — |
Kas dari pembiayaan | 18,25 jt | -22,58% |
Perubahan kas bersih | -18,65 jt | 28,58% |
Arus kas bebas | -23,15 jt | 18,17% |
Tentang
Anthera Pharmaceuticals, Inc. is an American biopharmaceutical company focused on developing and commercializing products to treat serious conditions associated with cystic fibrosis, inflammation and autoimmune diseases. Liprotamase, Anthera's leading drug candidate which is being developed for exocrine pancreatic insufficiency is currently in Phase 3 clinical trials, and A-623 for the treatment of IgA nephropathy is currently in Phase 2 clinical trial. Wikipedia
Didirikan
2004
Kantor pusat
Situs
Karyawan
21
